Orna Therapeutics is a technology company.
Orna Therapeutics has raised $320.0M across 3 funding rounds.
Orna Therapeutics has raised $320.0M in total across 3 funding rounds.
Orna Therapeutics has raised $320.0M in total across 3 funding rounds.
Orna Therapeutics's investors include Abingworth, ARCH Venture Partners, MPM Capital, Atlas Venture, Hakan Goker, Seroba Life Sciences, Taiho Ventures.
Orna Therapeutics is a biotechnology company developing fully engineered circular RNA (oRNA) therapeutics, a new class of RNA medicines designed to outperform traditional linear mRNA in protein expression, production simplicity, and delivery.[1][2][6] It builds oRNA platforms combined with proprietary lipid nanoparticle (LNP) delivery systems like panCAR™ for in vivo CAR therapies and STEM™ for bone marrow targeting, serving patients with oncology, autoimmune diseases, infectious diseases, and genetic disorders such as sickle cell disease and beta-thalassemia.[2][3][5] Orna solves key limitations of existing therapies—including ex vivo cell engineering's preconditioning needs, linear mRNA's immunogenicity and instability, and liver-only delivery—by enabling off-the-shelf, redosable treatments that generate multiple immune cell types in vivo with higher efficacy and lower risk.[2][3][4][5] The company shows strong growth momentum through an $80M+ Series A in 2021, a 2022 Merck collaboration on vaccines, and an advancing pipeline targeting IND filings by 2026.[3][4][6]
Founded in 2019 in Cambridge, Massachusetts, Orna Therapeutics emerged from groundbreaking MIT research on synthetic circular RNA, initially backed by MPM Capital with over $100M raised at launch in February 2021 via an $80M Series A.[1][6] The idea stemmed from nature-inspired rational design to overcome linear mRNA's flaws, like degradation and immune activation, by creating self-circularizing oRNA for superior stability and expression.[2][5][6] Key founders and leaders bring deep expertise: the team includes veterans in oRNA/LNP development, drug programs like the approved BEQVEZ for hemophilia B, and spin-outs like Cerevel Therapeutics from Pfizer.[7] Early traction came from platform validation in preclinical data for panCAR™ in autoimmune and oncology, plus the Merck partnership in 2022, positioning Orna as a leader in RNA innovation.[2][3][4]
Orna stands out through its integrated oRNA and LNP platforms, delivering advantages over linear mRNA and cell therapies:
Orna rides the RNA therapeutics revolution post-mRNA vaccines, extending it beyond liver targets and infectious diseases into oncology, autoimmunity, and genetics via circular RNA's durability and novel LNPs.[2][5] Timing is ideal amid surging demand for in vivo CAR therapies—avoiding ex vivo manufacturing bottlenecks—and rising focus on scalable, patient-friendly alternatives to viral vectors or preconditioned cell therapies.[3][4] Market forces like Merck's validation, preclinical successes, and RNA's cost-effective scalability favor Orna, influencing the ecosystem by redefining RNA as a versatile, "fully engineered" modality that could disrupt $100B+ immunotherapy and gene-editing markets.[2][6] It accelerates "off-the-shelf" innovation, lowering barriers for hard-to-treat indications and inspiring hybrid RNA platforms.[1][5]
Orna is poised for clinical breakthroughs, with panCAR™ INDs targeted by 2026, Merck milestones, and expansion into genetic diseases via STEM™.[3] Trends like AI-optimized RNA design, non-liver LNPs, and in vivo immune engineering will propel it, potentially yielding first approvals in autoimmune/oncology by late 2020s. Its influence may evolve from platform pioneer to multi-product leader, reshaping RNA meds as the go-to for systemic diseases—unlocking the "limitless potential" of oRNA to transform patient care beyond linear limits.[2]
Orna Therapeutics has raised $320.0M across 3 funding rounds. Most recently, it raised $220.0M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2022 | $220.0M Series B | Abingworth, ARCH Venture Partners, MPM Capital | |
| Feb 1, 2021 | $80.0M Series A | Abingworth, ARCH Venture Partners, Atlas Venture, MPM Capital, Hakan Goker, Seroba Life Sciences, Taiho Ventures | |
| Dec 1, 2019 | $20.0M Seed | Abingworth, ARCH Venture Partners, Atlas Venture, MPM Capital |